Physician profile
Candra Manley
NPI 1316482185
$1,921.13
in general payments reported to CMS, 2019-2025
19 companies · $613 in 2025
The $613 reported for 2025 was more than what 80% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $370 · 2022: $251 · 2023: $331 · 2024: $356 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $675.30 | 2022-2025 | |
| Shield Therapeutics INC | $305.55 | 2024-2025 | |
| Galderma Laboratories, L.P. | $169.57 | 2021 | |
| Sumitomo Pharma America, INC. | $154.70 | 2024-2025 | Myfembree |
| Regeneron Healthcare Solutions, INC. | $128.21 | 2021 | |
| Biogen, INC. | $125.38 | 2024-2025 | Zurzuvae |
| Allergan, INC. | $112.55 | 2022 | |
| Novo Nordisk INC | $32.38 | 2024 | Wegovy |
| Davol INC. | $32.27 | 2021 | |
| Janssen Pharmaceuticals, INC | $28.44 | 2025 | Spravato |
| Intersect Ent, INC. | $27.57 | 2021 | |
| Supernus Pharmaceuticals, INC. | $22.41 | 2025 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $20.06 | 2025 | |
| Noven Therapeutics, LLC | $17.76 | 2025 | Xelstrym |
| Hologic Sales and Service, LLC | $14.82 | 2024 | Acessa Provu System |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.44 | 2025 | Gardasil 9 |
| Teva Pharmaceuticals USA, INC. | $13.90 | 2025 | Austedo Xr |
| Medtronic, INC. | $13.20 | 2024 | Ligasure |
| Endo Pharmaceuticals INC. | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candra Manley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.